![Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera | Nature Medicine Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01270-4/MediaObjects/41591_2021_1270_Fig1_HTML.png)
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera | Nature Medicine
![Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome | Nature Medicine Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-018-0338-6/MediaObjects/41591_2018_338_Fig1_HTML.png)
Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome | Nature Medicine
![Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine | Nature Medicine Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01316-7/MediaObjects/41591_2021_1316_Fig1_HTML.png)
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine | Nature Medicine
![Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes | Nature Medicine Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-0932-2/MediaObjects/41591_2020_932_Fig1_HTML.png)
Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes | Nature Medicine
![Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report | Nature Medicine Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-019-0611-3/MediaObjects/41591_2019_611_Fig1_HTML.png)
Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report | Nature Medicine
![Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination | Nature Medicine Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01464-w/MediaObjects/41591_2021_1464_Fig1_HTML.png)
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination | Nature Medicine
![SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes | Nature Medicine SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-0868-6/MediaObjects/41591_2020_868_Fig1_HTML.png)
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes | Nature Medicine
![Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 | Nature Medicine Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01325-6/MediaObjects/41591_2021_1325_Fig1_HTML.png)